ESVS 2024 Guidelines: What Changes for Peripheral Artery Disease

Citable definition: Peripheral artery disease (PAD), also known as peripheral arterial disease, is a cardiovascular condition caused by atherosclerosis — the buildup of plaque in the arteries that supply the lower limbs. It affects approximately 3% of adults under 50 and up to 20% of people over 70 worldwide. The 2024 guidelines from the European Society for Vascular Surgery (ESVS) represent the most significant update to PAD management in a decade (Nordanstig J et al., EJVES, 2024, PMID 37949800).

The ESVS 2024 Guidelines: A Major Update for PAD

In January 2024, the European Society for Vascular Surgery (ESVS) published its new clinical practice guidelines on the management of asymptomatic lower limb PAD and intermittent claudication. This is the most anticipated update in the vascular field in over a decade.

These guidelines — clinical recommendations developed by a panel of European experts — are based on a comprehensive analysis of the most recent clinical trial evidence. They fundamentally change three domains: medical therapy, the role of exercise, and the criteria for revascularization.

For patients with PAD, these changes are concrete and actionable. Here is what you need to know.

Why Do These Guidelines Matter?

PAD is not an isolated disease of the legs. It is a powerful marker of overall cardiovascular risk. A patient with PAD has a two- to three-fold higher risk of heart attack and stroke compared to the general population.

For years, PAD management has been fragmented. Medical therapy was sometimes underutilized. Exercise was recommended without clear structure. Surgery was sometimes proposed too early.

The ESVS 2024 guidelines address these gaps with recommendations grounded in high levels of evidence.

What Changes: Medical Therapy

High-Intensity Statins for All — No Exceptions

This is the most structurally significant change in the ESVS 2024 guidelines.

Previously, statin prescribing for PAD patients took baseline LDL cholesterol into account. If LDL was “normal,” some clinicians hesitated to prescribe or stayed with lower doses.

The ESVS 2024 guidelines are unequivocal: all patients with PAD should receive a high-intensity statin, regardless of their baseline LDL. This means atorvastatin 40–80 mg or rosuvastatin 20–40 mg.

Why? Because statins do more than lower cholesterol. They stabilize atherosclerotic plaques, reduce vascular inflammation, and decrease amputation risk by 35% and mortality by 42% in PAD patients (Sagris M et al., Vasa, 2022, PMID 35673949). These benefits are observed regardless of baseline LDL.

For more on how statins work, see our comprehensive guide on statins in vascular disease.

A Lowered LDL Target: < 1.4 mmol/L (55 mg/dL)

PAD is now classified among very high cardiovascular risk conditions, on the same level as recent heart attack or ischemic stroke.

At this risk level, the guidelines recommend achieving an LDL cholesterol below 1.4 mmol/L (55 mg/dL) — along with at least a 50% reduction from baseline LDL. These thresholds align with the ESC/EAS 2019 recommendations (PMID 31504418) and are reinforced by the ESVS 2024.

In practice, this means that many PAD patients are not currently at target with their existing treatment. A reassessment of dose or molecule is often necessary.

Antiplatelet Therapy: No Major Changes

Aspirin (or clopidogrel) remains recommended for symptomatic patients. The guidelines specify indications for dual antiplatelet therapy and the combination of aspirin plus low-dose rivaroxaban (based on the COMPASS trial, PMID 29084692), but without a paradigm shift from previous recommendations.

What Changes: Supervised Exercise Takes Center Stage

A Quiet Revolution with Decisive Impact

The ESVS 2024 guidelines elevate supervised exercise therapy to the rank of first-line treatment for stable intermittent claudication — walking pain without immediate limb threat.

In concrete terms, this means that before considering revascularization (angioplasty or surgery), patients should complete a supervised exercise program of at least 12 weeks.

What Do the Studies Show?

The CLEVER trial (Murphy TP et al., Circulation, 2012, PMID 22090168) compared supervised exercise to angioplasty in claudicants. At 18 months, patients in the exercise group had walking performance superior to those who underwent surgery. Results from the ERASE trial (Hageman D et al., Eur J Vasc Endovasc Surg, 2018, PMID 29526597) point in the same direction.

Exercise works through several mechanisms: development of collateral circulation (new vessels that bypass blocked arteries), improved oxygen utilization by muscles, and reduction in systemic inflammation.

In Practice: What Is a Supervised Exercise Program?

A supervised exercise program for PAD typically includes:

• Treadmill walking or cycling sessions, 3 times per week
• A minimum duration of 30 to 45 minutes per session
• Supervision by a trained exercise physiologist or physical therapist
• Regular medical follow-up to adjust intensity

These programs are offered through cardiac and vascular rehabilitation centers in many countries. Your primary care physician or vascular specialist can refer you and assess whether this program is right for you.

What Changes: Revascularization Thresholds

Fewer Procedures for Stable Claudicants

This is one of the most important messages from the ESVS 2024: do not operate too early.

For patients with stable claudication (tolerable walking pain, no limb threat), revascularization should only be considered after failure of optimal medical therapy and supervised exercise. Claudication alone does not justify immediate intervention.

Critical Limb Ischemia: A Vascular Emergency

At the other end of the spectrum, the ESVS 2024 guidelines emphasize the need for rapid action in critical limb ischemia — the most severe stage of PAD. The criteria are precise:

Critical limb ischemia is a vascular emergency. If you experience rest pain in your foot or have a wound on your leg that will not heal, call emergency services or go to a vascular center without delay.

At a Glance: Previous vs. New ESVS Guidelines

What You Can Do Today

These new guidelines call for an active reassessment of many PAD patients. Here is what you can do right now:

1. Check your LDL level: are you at the < 1.4 mmol/L target? Ask your doctor to review your lipid panel.
2. Review your statin therapy: are you on a high-intensity statin? A dose adjustment may be needed.
3. Ask about supervised exercise: before any discussion of surgery, have you completed a structured exercise program of at least 12 weeks?
4. Watch for warning signs: rest pain, non-healing wounds, a cold foot — these are alarm signals that require urgent consultation.

See our comprehensive guide on peripheral artery disease: symptoms, diagnosis, and treatment for more on these topics.

When to See Your Doctor

See your doctor if:

• You have been diagnosed with PAD and your statin therapy has not been reassessed since 2024
• Your LDL cholesterol is above 1.4 mmol/L (55 mg/dL) despite treatment
• You experience leg pain on walking and have never participated in a supervised exercise program
• You have rest pain in your foot, especially at night
• A wound on your lower limbs is not healing properly

For a complete vascular evaluation aligned with the ESVS 2024 guidelines, consult your primary care physician or a vascular specialist.

Read also:

• Peripheral Artery Disease: Symptoms, Diagnosis, and Treatment
• Statins: Benefits, Side Effects, and Vascular Treatment
• Exercise and Blood Circulation: Best Activities for Your Vessels

References

1. Nordanstig J, James S, Andersson M et al. (ESVS Guidelines Committee). European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg. 2024; 67(1): 9-96. PMID 37949800

2. Sagris M, Katsaros I, Giannopoulos S et al. Statins and statin intensity in peripheral artery disease. Vasa. 2022; 51(4): 198-211. PMID 35673949

3. Murphy TP, Cutlip DE, Regensteiner JG et al. (CLEVER Trial). Supervised Exercise Versus Primary Stenting for Claudication Resulting From Aortoiliac Peripheral Artery Disease. Circulation. 2012; 125(1): 130-9. PMID 22090168

4. Hageman D, Fokkenrood HJP, Gommans LNM et al. (ERASE Trial). Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Eur J Vasc Endovasc Surg. 2018; 55(3): 352-361. PMID 29526597

5. Eikelboom JW, Connolly SJ, Bosch J et al. (COMPASS Trial). Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. NEJM. 2017; 377(14): 1319-1330. PMID 29084692

6. ESC/EAS Guidelines for the management of dyslipidaemias (2019). European Heart Journal. PMID 31504418

This article was written by the Petit Veinard Editorial Board and reviewed according to our editorial standards. It is not a substitute for professional medical advice. Always consult your doctor about any questions regarding your health.